ASH 2019 Highlights

CME

New Insights in Hematologic Malignancies and Disorders: Independent Conference Coverage of the 2019 ASH Annual Meeting

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: March 17, 2020

Expiration: March 16, 2021

Jeffrey P. DONOTUSESharman
Jeffrey P. DONOTUSESharman, MD
Rami S. Komrokji
Rami S. Komrokji, MD
Sagar Lonial
Sagar Lonial, MD, FACP
Sujit Sheth
Sujit Sheth, MD
Eunice S. Wang
Eunice S. Wang, MD

Activity

Progress
1
Course Completed

In these highlights from the ClinicalThought program, expert faculty members Jeff P. Sharman, MD; Hanny Al-Samkari, MD; Sujit Sheth, MD; Eunice S. Wang, MD; Rami S. Komrokji, MD; and Sagar Lonial, MD highlight key findings in chronic lymphocytic leukemia (CLL) and lymphomas, leukemias, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs), multiple myeloma (MM), and nonmalignant hematologic disorders presented at the 2019 ASH annual meeting.

CCO plans to measure the educational impact of this activity, and some questions in this activity will be asked twice: once before the discussion that informs the best choice and then once again after that specific discussion. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing clinician, how many patients with a hematologic malignancy do you provide care for in a typical month?

Which of the following BTK inhibitors is approved as initial therapy for a symptomatic patient with CLL and FISH results that include del(11q) positive, del(17p) negative, and unmutated IGHV?

In the phase III QUAZAR AML-001 study, patients with acute myeloid leukemia (AML) treated with oral azacitidine (CC-486) maintenance therapy for 12 months after achieving a CR showed a statistically significant improvement in median OS vs placebo (24.7 vs 14.8 months, respectively; P = .0009). This OS improvement was reported for which of the following groups of patients?

In the updated analysis of the phase III MEDALIST study that assessed luspatercept vs placebo for treating anemia in lower-risk, red blood cell (RBC) transfusion–dependent MDS with ring sideroblasts, which of the following accurately describes transfusion independence outcomes with luspatercept over the course of the study?

A 63-year-old man presented to the clinic with bone pain. Initial examination showed: anemia with hemoglobin of 10.2 g/dL; serum electrophoresis showed M-spike of 4.2 g/dL, immunofixation: IgG kappa; bone marrow aspirate: 30% plasma cells; and cytogenetics (FISH): t(11;14). Low-dose whole-body CT showed diffuse bone lesions on the spine. Creatinine is 80 mM/L; β2-microglobulin is 2.5 mg/L; albumin is 3.8 g/dL; and lactate dehydrogenase < normal.

In your current practice, what induction regimen would you recommend for this patient with newly diagnosed MM?